These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18519777)

  • 41. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
    Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
    J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
    Furth AF; Mandrekar SJ; Tan AD; Rau A; Felten SJ; Ames MM; Adjei AA; Erlichman C; Reid JM
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):39-45. PubMed ID: 17909811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ishill N; Sweeney SM; Deluca JK; Schwartz L; Bacik J; Motzer RJ
    Invest New Drugs; 2006 Nov; 24(6):543-6. PubMed ID: 16832603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
    Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R; Phelps MA; Marcucci G; Blum KA; Blum W
    Leuk Lymphoma; 2013 Sep; 54(9):1996-2002. PubMed ID: 23256542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
    Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
    Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
    Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
    Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis.
    Katragadda U; Fan W; Wang Y; Teng Q; Tan C
    PLoS One; 2013; 8(3):e58619. PubMed ID: 23505544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
    Lokich JJ; Anderson N; Bern M; Coco F; Dow E
    Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
    Löffler TM; Freund W; Lipke J; Hausamen TU
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
    Pauer LR; Olivares J; Cunningham C; Williams A; Grove W; Kraker A; Olson S; Nemunaitis J
    Cancer Invest; 2004; 22(6):886-96. PubMed ID: 15641487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
    Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
    Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.
    Jones S; Hainsworth J; Burris HA; Thompson D; Raefsky E; Johnson V; Calvert S; Bulanhagui C; Lebwohl D; Greco FA
    Invest New Drugs; 2002 Feb; 20(1):55-61. PubMed ID: 12008664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
    Grem JL; Morrison G; Guo XD; Agnew E; Takimoto CH; Thomas R; Szabo E; Grochow L; Grollman F; Hamilton JM; Neckers L; Wilson RH
    J Clin Oncol; 2005 Mar; 23(9):1885-93. PubMed ID: 15774780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.